A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

496

Enrollment

INDUSTRY

Sponsor class

Conditions

Early-stage Parkinson's Disease

Interventions

DRUG: UCB0599
DRUG: Placebo

Sponsor

UCB Biopharma SRL

Collaborators

[object Object]